Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Depreciation & Amortization (CF) (2016 - 2025)

Vanda Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $304000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 16.03% year-over-year to $304000.0; the TTM value through Dec 2025 reached $1.1 million, up 22.56%, while the annual FY2025 figure was $1.1 million, 22.56% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $304000.0 at Vanda Pharmaceuticals, up from $301000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $345000.0 in Q1 2021 and bottomed at $200000.0 in Q3 2023.
  • The 5-year median for Depreciation & Amortization (CF) is $287500.0 (2022), against an average of $275150.0.
  • The largest annual shift saw Depreciation & Amortization (CF) plummeted 33.11% in 2023 before it skyrocketed 39.35% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $337000.0 in 2021, then decreased by 15.73% to $284000.0 in 2022, then fell by 27.82% to $205000.0 in 2023, then rose by 27.8% to $262000.0 in 2024, then grew by 16.03% to $304000.0 in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Depreciation & Amortization (CF) are $304000.0 (Q4 2025), $301000.0 (Q3 2025), and $267000.0 (Q2 2025).